glp 1 glucagon Glucagon-like peptide-1 (GLP-1), released from the intestine, informs The Effects of Dual GLP-1/GIP

2022CX7HTJ

Several companies have GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists in phase 1 studies, including SCO-094 (Scohia Pharma), VK2735 (Viking Therapeutics) and CT-388 (Carmot Therapeutics)

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Bizino M.B., Jazet I.M., Westenberg J.J.M., van Eyk H.J., Paiman E.H.M., Smit J.W.A., Lamb H.J

These results were independent of the duration of treatment, the type of control, and the indication for GLP-1 receptor agonist treatment [13]